| A new inhibitor of the β-arrestin/AP2 endocytic complex reveals interplay between GPCR internalization and signalling A Beautrait, JS Paradis, B Zimmerman, J Giubilaro, L Nikolajev, ... Nature communications 8 (1), 15054, 2017 | 142 | 2017 |
| Receptor sequestration in response to β-arrestin-2 phosphorylation by ERK1/2 governs steady-state levels of GPCR cell-surface expression JS Paradis, S Ly, É Blondel-Tepaz, JA Galan, A Beautrait, MGH Scott, ... Proceedings of the National Academy of Sciences 112 (37), E5160-E5168, 2015 | 53 | 2015 |
| Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for GNAQ-Driven Uveal Melanoma JS Paradis, M Acosta, R Saddawi-Konefka, A Kishore, S Lubrano, ... Clinical Cancer Research 27 (11), 3190-3200, 2021 | 47 | 2021 |
| A biosensor to monitor dynamic regulation and function of tumour suppressor PTEN in living cells E Lima-Fernandes, S Misticone, C Boularan, JS Paradis, H Enslen, ... Nature communications 5 (1), 4431, 2014 | 27 | 2014 |
| NF45 and NF90 regulate mitotic gene expression by competing with staufen-mediated mRNA decay S Nourreddine, G Lavoie, J Paradis, KB El Kadhi, A Meant, L Aubert, ... Cell reports 31 (7), 2020 | 22 | 2020 |
| The RanBP2/RanGAP1-SUMO complex gates β-arrestin2 nuclear entry to regulate the Mdm2-p53 signaling axis E Blondel-Tepaz, M Leverve, B Sokrat, JS Paradis, M Kosic, K Saha, ... Oncogene 40 (12), 2243-2257, 2021 | 12 | 2021 |
| Establishment of a novel cancer cell line derived from vulvar carcinoma associated with lichen sclerosus exhibiting a fibroblast-dependent tumorigenic potential H Dongre, N Rana, S Fromreide, S Rajthala, IB Engelsen, J Paradis, ... Experimental Cell Research 386 (1), 111684, 2020 | 10 | 2020 |
| A new inhibitor of the beta-arrestin/AP2 endocytic complex reveals interplay between GPCR internalization and signalling. Nat Commun 8: 15054 A Beautrait, JS Paradis, B Zimmerman, J Giubilaro, L Nikolajev, ... doi. org/10.1038/ncomms15054, 2017 | 9 | 2017 |
| Computationally designed GPCR quaternary structures bias signaling pathway activation JS Paradis, X Feng, B Murat, RE Jefferson, B Sokrat, M Szpakowska, ... Nature communications 13 (1), 6826, 2022 | 8 | 2022 |
| Synergistic antitumor efficacy of the dual RAF/MEK inhibitor VS-6766 with FAK inhibition for treatment of RAS-dependent solid tumors S Coma, M Musteanu, JS Paradis, JS Gutkind, M Barbacid, JA Pachter Cancer Research 81 (13), 2021 | 3 | 2021 |
| Correction: Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for GNAQ-Driven Uveal Melanoma JS Paradis, M Acosta, R Saddawi-Konefka, A Kishore, S Lubrano, ... Clinical Cancer Research 27 (16), 4664-4664, 2021 | 2 | 2021 |
| Gαs is dispensable for β-arrestin coupling but dictates GRK selectivity and is predominant for gene expression regulation by β2-adrenergic receptor V Burghi, JS Paradis, A Officer, SR Adame-Garcia, X Wu, ESF Matthees, ... Journal of Biological Chemistry 299 (11), 2023 | | 2023 |
| Anticancer treatment for uveal melanoma J Gutkind, D Schlaepfer, J Paradis, A Kishore, M Acosta, N Arang US Patent 11,679,113, 2023 | | 2023 |
| Computationally designed GPCR quaternary structures bias signaling pathway activation R Jefferson, X Feng, P Barth, J Paradis, M Bouvier, A Chevigne, ... Protein Science 30, 51-51, 2021 | | 2021 |
| FAK and MEK co-targeting: A new multimodal precision therapy for GNAQ-driven uveal melanoma JS Paradis, M Acosta, N Arang, R Saddawi-Konefka, A Kishore, T Sugase, ... Cancer Research 80 (16_Supplement), 6406-6406, 2020 | | 2020 |
